The First People's Hospital of Neijiang
6
0
3
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
ICIs With and Without MWA in Advanced Hepatocellular Carcinoma
Role: lead
Composite Warming Strategy Reduces Intraoperative Hypothermia in Open Hepatectomy for Liver Cancer
Role: lead
Efficacy and Safety of High-Flow Nasal Cannula Versus Noninvasive Ventilation for Pulmonary Arterial Hypertension-Associated Acute Respiratory Failure
Role: lead
Efficacy and Safety of High-Dose Rate Brachytherapy with Immunotherapy and Chemotherapy As Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
Role: lead
Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China
Role: collaborator
Prediction of Adverse Perinatal Outcome for Preeclampsia in Sichuan Province of China
Role: collaborator
All 6 trials loaded